Learn about treatments for OA knee pain. Watch video.

Doxycycline Calcium

Pronunciation

Class: Tetracyclines
Note: This monograph also contains information on Doxycycline Hyclate, Doxycycline Monohydrate
VA Class: AM250
CAS Number: 24390-14-5
Brands: Doryx, Doxy 100, Monodox, Vibramycin, Vibra-Tabs

Introduction

Antibacterial; semisynthetic tetracycline antibiotic derived from oxytetracycline.103 111 113 114

Uses for Doxycycline Calcium

Respiratory Tract Infections

Treatment of respiratory tract infections caused by Mycoplasma pneumoniae.111 113 114

Treatment of respiratory tract infections caused by Haemophilus influenzae, Streptococcus pneumoniae, or Klebsiella.111 113 114 Should only be used for treatment of infections caused by these bacteria when in vitro susceptibility tests indicate the organism is susceptible.111 113 a

Empiric treatment of community-acquired pneumonia (CAP) in conjunction with other anti-infectives.a Tetracyclines provide coverage against C. pneumoniae, M. pneumoniae, H. influenzae, and Legionella, but S. pneumoniae may be resistant.a Doxycycline is the preferred tetracycline for empiric treatment of CAP.a

Alternative for treatment of infections caused by Legionella pneumophila; 137 used with or without rifampin.137

Acne

Adjunctive treatment of moderate to severe inflammatory acne.111 a Not indicated for treatment of noninflammatory acne.a

Actinomycosis

Treatment of actinomycosis caused by Actinomyces israelii.111 113 137 Alternative to penicillin G;111 113 137 oral tetracyclines (usually doxycycline or tetracycline) also used as follow-up after initial parenteral penicillin G.109

Amebiasis

Adjunct to amebicides for treatment of acute intestinal amebiasis.111 113 Tetracyclines not included in current recommendations for treatment of amebiasis caused by Entamoeba.109 122

Anthrax

Postexposure prophylaxis to reduce the incidence or progression of disease following a suspected or confirmed exposure to aerosolized Bacillus anthracis spores (inhalational anthrax).102 111 113 141 147 Initial drug of choice for such prophylaxis is ciprofloxacin or doxycycline;102 141 147 doxycycline is the preferred tetracycline because of ease of administration and proven efficacy in monkey studies.102

Treatment of inhalational anthrax.102 111 113 142 143 147 o Monotherapy may be effective for anthrax that occurs as the result of natural or endemic exposures,109 o but a multiple-drug parenteral regimen (ciprofloxacin or doxycycline and 1 or 2 other anti-infectives predicted to be effective) is recommended for inhalational anthrax that occurs as the result of exposure to anthrax spores in the context of biologic warfare or bioterrorism.102 143 147 Although tetracyclines not usually used in children <8 years of age or in pregnant women, the benefits of doxycycline outweigh the risks and CDC and others state doxycycline can be used when necessary for treatment of inhalational anthrax in these individuals.102 105 143 147

Treatment of GI and oropharyngeal anthrax.102 143 If occurring in the context of biologic warfare or bioterrorism, use parenteral regimens recommended for inhalational anthrax.102 143

Treatment of cutaneous anthrax.102 111 143 147 o Multiple-drug regimen recommended for initial treatment when there are signs of systemic involvement, extensive edema, or lesions on the head or neck or when cutaneous anthrax occurs in children <2 years of age.102 105 143 147 o

Bartonella Infections

Treatment of bartonellosis caused by Bartonella bacilliformis.111 113 160

Treatment of infections caused by B. henselae (e.g., cat scratch disease, bacillary angiomatosis, peliosis hepatitis).i Cat scratch disease generally is self-limited in immunocompetent individuals and may resolve spontaneously in 2–4 months; some clinicians suggest that anti-infective therapy be considered for acutely or severely ill patients with systemic symptoms, particularly those with hepatosplenomegaly or painful lymphadenopathy, and probably is indicated in immunocompromised patients.109 j k l Anti-infectives also are indicated in patients with B. henselae infections who develop bacillary angiomatosis, neuroretinitis, or Parinaud’s oculoglandular syndrome.109 j k l Optimum regimens have not been identified; some clinicians recommend erythromycin, azithromycin, doxycycline, ciprofloxacin, rifampin, co-trimoxazole, gentamicin, or third generation cephalosporins.109 i j k l

Treatment of infections caused by B. quintana.137 Optimum anti-infective regimens have not been identified;e f g various drugs have been used, including doxycycline, erythromycin, azithromycin, chloramphenicol, or cephalosporins.137 f g

A drug of choice for treatment of bartonellosis in HIV-infected adults and adolescents, especially CNS bartonellosis.160 USPHS/IDSA, CDC, and others suggest that long-term suppression with erythromycin or doxycycline should be considered to prevent recurrence of bartonellosis in HIV-infected adults and adolescents with relapse or reinfection.160 h

Brucellosis

Treatment of brucellosis;103 109 111 113 114 137 147 m considered a drug of choice.109 147 Used in conjunction with other anti-infectives (e.g., streptomycin or gentamicin and/or rifampin),103 109 111 113 114 137 147 m especially for severe infections or when there are complications (e.g., endocarditis, meningitis, osteomyelitis).109 147

Postexposure prophylaxis following a high-risk exposure to Brucella109 147 (e.g., needle-stick injury, inadvertent laboratory exposure, confirmed exposure in the context of biologic warfare or bioterrorism).147 Postexposure prophylaxis not generally recommended after exposure to endemic brucellosis.109 147

Slideshow: View Frightful (But Dead Serious) Drug Side Effects

Burkholderia Infections

Treatment of melioidosis caused by Burkholderia pseudomallei.137 147 gg Although optimum regimens not identified, doxycycline monotherapy may be effective for mild, localized disease without toxicity, and doxycycline in conjunction with co-trimoxazole may be effective for localized disease with toxicity.147 Severe illness requires an initial parenteral regimen of ceftazidime, imipenem, or meropenem (with or without concomitant co-trimoxazole or doxycycline), followed by a prolonged oral maintenance regimen of doxycycline (in conjunction with co-trimoxazole) or amoxicillin-clavulanate.147 gg

Treatment of glanders caused by B. mallei.137 Experience is limited regarding treatment of human cases; optimum regimens not identified.147 gg Some clinicians suggest streptomycin used in conjunction with tetracycline or chloramphenicol or imipenem monotherapy.137 Others suggest that, pending results of in vitro susceptibility tests, regimens used for treatment of melioidosis can be used for initial empiric treatment of glanders.147

The US Army Medical Research Institute of Infectious Diseases (USAMRIID) and European Commission’s Task Force on Biological and Chemical Agent Threats (BICHAT) state that the same treatment regimens recommended for naturally occurring melioidosis or glanders should be used if these Burkholderia infections occur in the context of biologic warfare or bioterrorism.147 gg These experts suggest that postexposure prophylaxis with doxycycline or co-trimoxazole for ≥10 days can be attempted in such situations, but is of unproven benefit.147 gg

Campylobacter Infections

Treatment of infections caused by Campylobacter fetus.103 111 114 Tetracyclines (usually doxycycline) are alternatives,109 not drugs of choice for C. fetus.137

Chancroid

Treatment of chancroid caused by Haemophilus ducreyi.103 111 113 114 Not included in CDC recommendations for treatment of chancroid.107

Chlamydial Infections

Treatment of uncomplicated urethral, endocervical, or rectal infections caused by Chlamydia trachomatis.107 108 109 111 114 137 A drug of choice for presumptive treatment of chlamydial infections in patients with gonorrhea.107 108

Treatment of trachoma and inclusion conjunctivitis caused by C. trachomatis.109 111 113 114 Consider that anti-infectives may not eliminate C. trachomatis in all cases of chronic trachoma.111 113 114

Treatment of lymphogranuloma venereum (genital, inguinal, or anorectal infections) caused by C. trachomatis.103 107 108 111 113 114 Recommended as drug of choice by CDC and others.107 108

Treatment of psittacosis (ornithosis) caused by C. psittaci.100 103 109 111 113 114 A drug of choice recommended by CDC.100

Clostridium Infections

Treatment of infections caused by Clostridium.111 113 Tetracyclines are alternatives to metronidazole or penicillin G for adjunctive treatment of C. tetani infections.137

Ehrlichiosis

Treatment of human granulocytotropic (or granulocytic) anaplasmosis (HGA; formerly human granulocytic ehrlichiosis [HGE]) caused by Anaplasma phagocytophilum (formerly Ehrlichia phagocytophila, E. equi, agent of HGE); drug of choice.109 137 x z cc

Treatment of human monocytotropic (or monocytic) ehrlichiosis (HME) caused by E. chaffeensis; drug of choice.109 137 x cc

Treatment of ehrlichiosis caused by E. ewingii or E. canis; drug of choice.109 137 cc

Enterobacteriaceae Infections

Treatment of infections caused by susceptible Escherichia coli, Enterobacter aerogenes, Klebsiella, or Shigella.111 113 Should only be used for treatment of infections caused by these common gram-negative bacteria when other appropriate anti-infectives are contraindicated or ineffectivea and when in vitro susceptibility tests indicate the organism is susceptible.111 113 a

Fusobacterium Infections

Alternative to penicillin G for treatment of infections caused by Fusobacterium fusiforme (Vincent’s infection).111 113

Gonorrhea and Associated Infections

Alternative for treatment of uncomplicated gonorrhea caused by susceptible Neisseria gonorrhoeae.111 113 114 However, tetracyclines are considered inadequate therapy and are not recommended by CDC for treatment of gonorrhea.107 b

Empiric treatment of epididymitis most likely caused by N. gonorrhoeae or C. trachomatis; used in conjunction with IM ceftriaxone.107 108

Granuloma Inguinale (Donovanosis)

Treatment of granuloma inguinale (donovanosis) caused by Calymmatobacterium granulomatis.107 111 113 114 CDC recommends doxycycline or co-trimoxazole as drugs of choice.107

Leptospirosis

Alternative to penicillin G for treatment of leptospirosis.109 137

Prevention of leptosporosis in travelers to areas where leptospirosis is endemic or epidemic who are at increased risk (e.g., those who engage in recreational water activities such as whitewater rafting, adventure racing, kayaking).123 153

Can be used for combined prophylaxis in travelers at increased risk of leptospirosis who also require malaria chemoprophylaxis.123

Listeria Infections

Alternative for treatment of listeriosis caused by Listeria monocytogenes.111 113 Not usually considered a drug of choice or alternative for these infections.109 137

Lyme Disease

Treatment of early disseminated Lyme disease associated with erythema migrans, in the absence of neurologic involvement or third-degree AV heart block.109 115 116 117 118 119 120 121 136 137 140 IDSA, AAP, and others recommend oral doxycycline or oral amoxicillin as first-line therapy for treatment of early localized or early disseminated Lyme disease when oral therapy is appropriate.109 115 116 117 118 119 120 121 136 137 140

Treatment of uncomplicated Lyme arthritis without objective evidence of neurologic involvement (e.g., meningitis or radiculopathy).109 115 116 117 121 136 140

Alternative for treatment of neurologic manifestations of Lyme disease when β-lactams (e.g., ceftriaxone, penicillin G) cannot be used.136

Malaria

Prevention (prophylaxis) of malaria caused by Plasmodium falciparum, including chloroquine-resistant strains.111 122 123 139 153 Recommended by CDC and others as a drug of choice for prophylaxis in individuals traveling to areas where chloroquine-resistant P. falciparum malaria has been reported;122 123 recommended by CDC as an alternative in those traveling to areas where chloroquine-resistant P. falciparum has not been reported and who are unable to take chloroquine or hydroxychloroquine.123

Treatment of uncomplicated malaria caused by chloroquine-resistant Plasmodium falciparum or chloroquine-resistant P. vivax and when the plasmodial species has not been identified.122 158 Used in conjunction with quinine; not effective alone.122 158

CDC and others state treatments of choice for uncomplicated chloroquine-resistant P. falciparum malaria are a regimen of oral quinine in conjunction with oral doxycycline, tetracycline, or clindamycin or a regimen of atovaquone and proguanil.122 158 A regimen of quinine and doxycycline (or tetracycline) generally preferred over quinine and clindamycin,158 except for young children or pregnant women who should not receive tetracyclines.158 Quinine in conjunction with tetracycline (or doxycycline) also a regimen of choice for chloroquine-resistant P. vivax malaria.122 158

Treatment of severe malaria caused by P. falciparum; used in conjunction with IV quinidine gluconate initially and then with oral quinine when an oral regimen is tolerated.158

Presumptive self-treatment of malaria in travelers who elect not to use prophylaxis, those who require or choose to use a prophylaxis regimen that may not have optimal efficacy, or for long-term travelers receiving effective prophylaxis but who plan to visit very remote areas; used in conjunction with quinine.122 Not recommended by CDC for presumptive self-treatment of malaria; CDC recommends the fixed combination of atovaquone and proguanil.123

Active only against the asexual erythrocytic forms of Plasmodium (not exoerythrocytic stages) and cannot prevent delayed primary attacks or relapse of P. ovale or P. vivax malaria or provide a radical cure;122 123 158 primaquine usually also indicated to eradicate hypnozoites and prevent relapse in patients exposed to or being treated for P. ovale or P. vivax malaria.122 123 158

Detailed recommendations regarding prevention of malaria available from CDC 24 hours a day from the voice information service (877-394-8747), fax information service (888-232-3299), or Internet at .123

Assistance with diagnosis or treatment of malaria available from CDC Malaria Epidemiology Branch by contacting CDC Malaria Hotline at 770-488-7788 from 8:00 a.m. to 4:30 p.m. Eastern Standard Time or CDC Emergency Operation Center at 770-488-7100 after hours, on weekends, and holidays.158

Mycobacterial Infections

Alternative for treatment of infections caused by Mycobacterium fortuitum.137

Treatment of cutaneous infections caused by M. marinum;106 137 a drug of choice.106

Nocardiosis

Alternative to co-trimoxazole for treatment of nocardiosis caused by Nocardia.109 137 a

Nongonococcal Urethritis

Treatment of nongonococcal urethritis (NGU) caused by Ureaplasma urealyticum, C. trachomatis, or Mycoplasma.107 108 111 114 b

Consider that some cases of recurrent urethritis following doxycycline treatment may be caused by tetracycline-resistant U. urealyticum.107

Pelvic Inflammatory Disease

Treatment of acute pelvic inflammatory disease (PID); used in conjunction with other anti-infectives.107 108 Doxycycline is included in PID regimens to provide coverage against Chlamydia.107

When a parenteral regimen is indicated for PID, CDC and others recommend IV cefotetan (or cefoxitin) in conjunction with IV or oral doxycycline as a regimen of choice.107 108 A regimen of IV ampicillin and sulbactam and IV doxycycline is an alternative107 108 since it provides good coverage against C. trachomatis, N. gonorrhoeae, and anaerobes and is effective for tubo-ovarian abscess.107 Doxycycline also used as follow-up after a parenteral regimen of clindamycin and gentamicin.107

When an oral regimen is indicated, CDC and others recommend a single IM dose of ceftriaxone or cefoxitin (or other parenteral cephalosporin) followed by oral doxycycline (with or without oral metronidazole) as a regimen of choice.107 108 Although experience is limited, oral amoxicillin and clavulanate and oral doxycycline may be an alternative oral regimen.107

Plague

Treatment of plague caused by Yersinia pestis,103 111 113 114 123 137 144 147 including naturally occurring or endemic bubonic, septicemic, or pneumonic plague and plague that occurs following exposure to Y. pestis in the context of biologic warfare or bioterrorism.137 144 147 Regimen of choice is streptomycin or gentamicin;137 144 147 alternatives are doxycycline, tetracycline, ciprofloxacin, or chloramphenicol.144 147 For plague meningitis, some experts recommend that treatment regimen include chloramphenicol.147

Postexposure prophylaxis following a high-risk exposure to Y. pestis (e.g., household, hospital, or other close contact with an individual who has pneumonic plague; laboratory exposure to viable Y. pestis; confirmed exposure to plague aerosol in the context of biologic warfare or bioterrorism).144 147 Doxycycline may be drug of choice;109 144 147 alternatives are tetracycline, ciprofloxacin, or chloramphenicol.147 Prophylaxis not required for asymptomatic contacts of individuals with bubonic plague, but observe such contacts for 1 week and initiate treatment if symptoms occur.147

Pleural Effusions

Management of pleural effusions associated with metastatic tumors.126 127 128 132 134 151 152

Rat-bite Fever

Treatment of rat-bite fever caused by Streptobacillus moniliformis or Spirillum minus.109 137 Tetracyclines (usually doxycycline) are alternatives to penicillin G.109 137

Relapsing Fever

Treatment of relapsing fever caused by Borrelia recurrentis.111 113 137 A drug of choice.137

Rickettsial Infections

Treatment of rickettsial infections including Rocky Mountain spotted fever (RMSF), typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae.103 109 111 112 113 114 147 cc Drug of choice for treatment of most rickettsial infections.109 112 147 a cc

Syphilis

Alternative to penicillin G benzathine for treatment of primary, secondary, latent, or tertiary syphilis (not neurosyphilis) in nonpregnant adults and adolescents hypersensitive to penicillins, including HIV-infected patients.107 108 109 111 113 160 Use tetracyclines only if compliance and follow-up can be ensured since efficacy not well documented.107 160

Tularemia

Treatment of tularemia caused by Francisella tularensis,103 111 113 114 137 145 147 including naturally occurring or endemic tularemia or tularemia that occurs following exposure to F. tularensis in the context of biologic warfare or bioterrorism.137 145 147 Drugs of choice are streptomycin or gentamicin; alternatives are tetracyclines (usually doxycycline), ciprofloxacin, or chloramphenicol.137 145 147 Risk of relapse and primary treatment failure may be higher with the alternatives.145

Postexposure prophylaxis of tularemia following a high-risk laboratory exposure to F. tularensis (e.g., spill, centrifuge accident, needlestick injury) or in individuals exposed to the organism in the context of biologic warfare or bioterrorism.145 147 Drugs of choice are doxycycline, tetracycline, or ciprofloxacin.145 147 Postexposure prophylaxis usually not recommended after exposure to natural or endemic tularemia (e.g., tick bite, rabbit or other animal exposure) and is unnecessary in close contacts of tularemia patients since human-to-human transmission does not occur.147

Preexposure prophylaxis of tularemia.147 Based on results of in vitro susceptibility data, use of doxycycline or ciprofloxacin before exposure possibly may protect against tularemia in the context of biologic warfare or bioterrorism.147

Vibrio Infections

Treatment of cholera caused by Vibrio cholerae.109 110 111 137 p A drug of choice; used as an adjunct to fluid and electrolyte replacement in moderate to severe disease.109 110 137 p

Treatment of severe V. parahaemolyticus infection when anti-infective therapy is indicated in addition to supportive care.p

Treatment of infections caused by V. vulnificus.137 p p Optimum anti-infective therapy has not been identified; a tetracycline or third generation cephalosporin (e.g., cefotaxime, ceftazidime) is recommended.137 p q Because the case fatality rate associated with V. vulnificus is high, initiate anti-infective therapy promptly if indicated.q

Yaws

Alternative to penicillin G for treatment of yaws caused by Treponema pertenue.111 137

Yersinia Infections

Treatment of plague caused by Yersinia pestis.103 111 113 114 137 144 147 (See Plague under Uses.)

Treatment of GI infections caused by Yersinia enterocolitica or Y. pseudotuberculosis.110 p These infections usually are self-limited, but IDSA, AAP, and others recommend anti-infectives for severe infections or when septicemia or other invasive disease occurs.109 110 p Some suggest the role of oral anti-infectives in management of enterocolitis, pseudoappendicitis syndrome, or mesenteric adenitis caused by Yersinia needs further evaluation.109

Prophylaxis in Sexual Assault Victims

Empiric anti-infective prophylaxis in sexual assault victims; used in conjunction with a drug effective for gonorrhea (IM ceftriaxone) and a drug effective for bacterial vaginosis and trichomoniasis (oral metronidazole).107 108

Doxycycline Calcium Dosage and Administration

Administration

Administer orally101 103 114 111 or by slow IV infusion.113 Also has been administered by intrapleural infusion.126 127 128 132 134 151 152

Do not administer IM or sub-Q.113

IV route recommended only when oral therapy is not indicated or feasible; oral should replace IV as soon as possible.113 Prolonged IV administration may result in thrombophlebitis; avoid extravasation.113

Oral Administration

Administer capsules and tablets with adequate amounts of fluid to reduce the risk of esophageal irritation and ulceration.103 114 111 123 Probably should not be given at bedtime or to patients with esophageal obstruction or compression.123 b

Administer with food or milk to minimize nausea and vomiting and if gastric irritation occurs;103 114 111 absorption not markedly influenced by simultaneous ingestion of food or milk.103 114 111 146 148 150

When used for prevention of malaria, CDC recommends taking the drug in the evening (but not at bedtime), avoiding prolonged, direct exposure to the sun, and use of sunscreens that absorb long-wave UVA radiation to minimize the risk of photosensitivity.123

Reconstitution

Reconstitute doxycycline monohydrate powder for oral suspension at the time of dispensing according to manufacturer’s directions to provide a suspension containing 25 mg/5 mL.111

Doxycycline calcium oral suspension is administered as provided without further dilution and contains 50 mg/5 mL.111

If necessary because the commercial powder for oral suspension and oral suspension are not available, doxycycline film-coated tablets can be ground and mixed with food or drinks.155 156 Ground doxycycline tablets are most palatable when mixed with chocolate pudding, regular or low-fat chocolate milk, simple syrup with sour apple flavor, apple juice with table sugar, or low-fat milk; the bitterness of the drug is not masked with grape or strawberry jellies or cherry yogurt.155

IV Infusion

For solution and drug compatibility information, see Compatibility under Stability.

Reconstitution

Reconstitute vial containing 100 or 200 mg with 10 or 20 mL, respectively, of sterile water for injection or a compatible IV infusion solution (see Compatibility under Stability) to provide a solution containing 10 mg/mL.113

Dilution

Reconstituted solution must be further diluted prior to administration.113 Each 100 mg should be diluted in 100 mL to 1 L of compatible IV infusion solution (see Compatibility under Stability) to provide solutions containing approximately 0.1–1 mg/mL.113 Concentrations <0.1 mg/mL or >1 mg/mL are not recommended.113

Rate of Administration

Administer by slow IV infusion, usually over 1–4 hours (depending on the dose).113 The minimum recommended time to infuse 100 mg in a solution containing 0.5 mg/mL is 1 hour.113

Intrapleural Administration

Reconstitution and Dilution

Dilute 500 mg of doxycycline with 25–30 mL of 0.9% sodium chloride injection.126 127 128 132 134 151 152

Intrapleural Administration Technique

Prior to intrapleural instillation of doxycycline solution, drain the pleural cavity by thoracentesis (needle aspiration) or via a thoracostomy tube by gravity or suction (i.e., closed chest tube drainage).127 128 130 131 133

Efficacy of the procedure may be reduced if fluid drainage from the chest tube is >100 mL/24 hours when doxycycline is introduced into the pleural cavity.130 131 133

Instill diluted doxycycline solution into the pleural space through a thoracostomy tube; clamp tube and subsequently remove the fluid.126 127 128 132 134 151 152

Dosage

Available as doxycycline calcium,111 doxycycline hyclate,103 111 113 and doxycycline monohydrate;111 114 dosage expressed in terms of doxycycline.103 111 113 114

Pediatric Patients

General Pediatric Dosage
Oral

Children >8 years of age weighing ≤45 kg: 4.4 mg/kg in 2 divided doses on day 1 followed by 2.2 mg/kg daily in 1 or 2 divided doses.103 111 114 For severe infections, up to 4.4 mg/kg daily.103 111 114

Children >8 years of age weighing >45 kg: 100 mg every 12 hours on day 1 followed by 100 mg daily in 1 or 2 divided doses.103 111 114 For more severe infections, 100 mg every 12 hours.103 111 114

IV

Children >8 years of age weighing ≤45 kg: 4.4 mg/kg in 1 or 2 divided doses on day 1 followed by 2.2–4.4 mg/kg daily in 1 or 2 infusions.113

Children >8 years of age weighing >45 kg: 200 mg on day 1 in 1 or 2 infusions followed by 100–200 mg daily.113

Anthrax
Postexposure Prophylaxis Following Exposure in the Context of Biologic Warfare or Bioterrorism
Oral

Children ≤8 years of age or weighing <45 kg: 2.2 mg/kg (up to 100 mg) twice daily given for ≥60 days.141 147 c Because of concerns regarding long-term doxycycline use in infants and children, consider changing (after 10–14 days) to amoxicillin to complete the prophylaxis regimen if penicillin susceptibility is confirmed.102 104 141 147

Children >8 years of age weighing ≥45 kg: 100 mg twice daily given for ≥60 days.104 141 147 c

Optimum duration of postexposure prophylaxis after an inhalation exposure to B. anthracis spores is unclear,147 ff but prolonged postexposure prophylaxis usually required.102 147 A duration of 60 days may be adequate for a low-dose exposure, but a duration >4 months may be necessary to reduce the risk following a high-dose exposure.ff CDC and US Working Group on Civilian Biodefense recommend that postexposure prophylaxis following a confirmed exposure (including in laboratory workers with confirmed exposures to B. anthracis cultures) be continued for 60 days.102 147 The US Army Medical Research Institute of Infectious Diseases (USAMRIID) recommends that postexposure prophylaxis be continued for at least 60 days in individuals who are not fully immunized against anthrax and when anthrax vaccine is unavailable or cannot be used for postexposure vaccination.147

Treatment of Inhalational, GI, or Oropharyngeal Anthrax
Oral

Children ≤8 years of age or weighing <45 kg: 2.2 mg/kg twice daily (up to 200 mg daily).102 147 c

Children >8 years of age weighing ≥45 kg: 100 mg twice daily.102 c Some experts recommend an initial 200-mg dose, then 100 mg every 12 hours.147

Initial parenteral regimen preferred; use oral regimen for initial treatment only when a parenteral regimen is not available (e.g., when there are supply or logistic problems because large numbers of individuals require treatment in a mass casualty setting).102 147 Continue for total duration of ≥60 days if inhalational anthrax occurred as the result of exposure to anthrax spores in the context of biologic warfare or bioterrorism.102 143 147 Because of concerns regarding long-term doxycycline use in infants and children, consider changing (after 10–14 days) to amoxicillin to complete the treatment regimen in children <8 years of age if penicillin susceptibility is confirmed.105

IV, then Oral

Children ≤8 years of age or weighing <45 kg: 2.2 mg/kg (up to 100 mg) twice daily.102 143 147 d

Children >8 years of age weighing ≥45 kg: 100 mg twice daily.102 142 143 147 d

Used in conjunction with 1 or 2 other anti-infectives predicted to be effective.102 143 147 When clinical improvement occurs, switch IV doxycycline to oral doxycycline in the same dosage and continue for a total duration of ≥60 days.102 142 143 147 d Because of concerns regarding long-term doxycycline use in infants and children, consider changing (after 10–14 days) to amoxicillin to complete the treatment regimen in children <8 years of age if penicillin susceptibility is confirmed.105

Treatment of Cutaneous Anthrax
Oral

Children ≤8 years of age or weighing <45 kg: 2.2 mg/kg (up to 100 mg) twice daily.102 143 147

Children >8 years of age weighing ≥45 kg: 100 mg twice daily.102 143 147

For mild, uncomplicated cutaneous anthrax that occurs following natural or endemic exposure, 5–10 days of treatment has been recommended.102 143 147

For cutaneous anthrax that occurs following exposure in the context of biologic warfare or bioterrorism, duration of treatment is ≥60 days.102 143 147 Because of concerns regarding long-term doxycycline use in infants and children, consider changing (after 10–14 days) to amoxicillin to complete the treatment regimen in children <8 years of age if penicillin susceptibility is confirmed.105 143 147

Oral regimen should not be used for initial treatment of cutaneous anthrax if there are signs of systemic involvement, extensive edema, or head and neck lesions and should not be used for initial treatment in infants and children <2 years of age.102 105 143 147

IV, then Oral

Children ≤8 years of age or weighing <45 kg: 2.2 mg/kg (up to 100 mg) twice daily.102 147

Children >8 years of age weighing ≥45 kg: 100 mg every 12 hours.102 142 143 147

Used in conjunction with 1 or 2 other anti-infectives predicted to be effective.102 143 147 When clinical improvement occurs, switch IV doxycycline to oral doxycycline in the same dosage and continue for a total duration of ≥60 days.102 142 143 147 d Because of concerns regarding long-term doxycycline use in infants and children, consider changing (after 10–14 days) to amoxicillin to complete the treatment regimen in children <8 years of age if penicillin susceptibility is confirmed.105 147

Bartonella Infections
Oral or IV

Adolescents with HIV infection: 100 mg every 12 hours for ≥3 months for bartonellosis (including CNS infections).160 Also consider doxycycline long-term suppressive therapy in those with relapse or reinfection.160

Brucellosis
Treatment of Brucellosis
Oral

Children ≥8 years of age: 2–4 mg/kg daily (up to 200 mg daily) in 2 divided doses.109 Some experts recommend 2.2 mg/kg twice daily (up to 200 mg daily).147

Usual duration of therapy is 4–6 weeks;109 147 more prolonged therapy may be required for complicated disease (e.g., hepatitis, splenitis, meningoencephalitis, endocarditis, osteomyelitis).147 Meningoencephalitis and endocarditis should be treated for ≥90 days and may require ≥6 months of treatment.147

Usually used in conjunction with rifampin or other anti-infectives to decrease risk of relapse.109 147 If infection is severe or if endocarditis, meningitis, or osteomyelitis is present, administer IM streptomycin or gentamicin during the first 1–3 weeks of doxycycline therapy.109 147

Burkholderia Infections
Initial Treatment of Severe Disease
IV

Children <8 years of age or weighing <45 kg: 2.2 mg/kg twice daily (up to 200 mg daily) given in conjunction with IV ceftazidime, imipenem, or meropenem.gg

Children ≥8 years of age or weighing ≥45 kg: 100 mg twice daily given in conjunction with IV ceftazidime, imipenem, or meropenem.gg

Initial IV regimen continued for ≥14 days and until clinical improvement occurs.147 gg When appropriate, switch to a prolonged oral maintenance regimen.147 gg

Follow-up Maintenance Regimen after Initial Treatment of Severe Disease
Oral

Children ≥8 years of age or weighing ≥45 kg: 100 mg twice daily given in conjunction with oral co-trimoxazole.147

Prolonged oral maintenance regimen recommended to reduce risk of relapse after initial treatment with IV ceftazidime, imipenem, or meropenem (with or without IV doxycycline).147 Maintenance regimen usually continued for ≥4–6 months;147 gg a duration of 6–12 months may be necessary depending on response to therapy and severity of illness.147 gg Lifelong follow-up recommended for all patients to identify relapse.147

Chlamydial Infections
Uncomplicated Urethral, Endocervical, or Rectal Infections
Oral

Children >8 years of age: 100 mg twice daily given for 7 days.107 109

Presumptive Treatment of Chlamydial Infection in Gonorrhea Patients
Oral

Adolescents: 100 mg twice daily given for 7 days.107

Lymphogranuloma Venereum
Oral

Adolescents: 100 mg twice daily given for 21 days.107 109

Ehrlichiosis
Oral or IV

AAP and CDC recommend 2.2 mg/kg (up to 100 mg) twice daily.109 cc Initiate promptly since delay can result in severe disease and fatal outcome.109 cc

Optimum duration of therapy not established.109 cc Usually continued ≥5–10 days and until patient is afebrile for ≥3 days and clinically improved.109 x cc Severe illness may require longer duration of therapy.109 cc CDC recommends a duration of 10–14 days in those with HGA since this provides an appropriate duration of therapy for possible concurrent early Lyme disease.cc

IV therapy generally indicated for hospitalized patients; oral therapy generally appropriate for patients with early disease, those treated as outpatients, or inpatients who are not vomiting or obtunded.109 cc

Gonorrhea and Associated Infections
Empiric Treatment of Epididymitis
Oral

Children ≥8 years of age: 100 mg twice daily given for 10 days; as follow-up to single-dose IM ceftriaxone.107 109

Granuloma Inguinale (Donovanosis)
Oral

Adolescents: 100 mg twice daily given for ≥3 weeks or until all lesions have healed completely;107 consider adding IV aminoglycoside (e.g., gentamicin) if improvement is not evident within the first few days of therapy and in HIV-infected patients.107

Relapse can occur 6–18 months after apparently effective treatment.116

Lyme Disease
Early Localized or Early Disseminated Lyme Disease
Oral

Children ≥8 years of age: 1–2 mg/kg in 2 divided doses (up to 100 mg each dose).109 115 116 117 118 119 120 121 124 136 137 140

Duration of treatment is 14–21 days for most patients with early localized or early disseminated disease in the absence of neurologic involvement.109 115 116 117 118 119 120 121 124 136 140 Some experts recommend a duration of 21–28 days for early disseminated disease associated with mild carditis or isolated facial nerve palsy.109 115 136 140

Lyme Arthritis
Oral

Children ≥8 years of age: 1–2 mg/kg twice daily (up to 100 mg each dose) for 28 days.109 115 116 117 119 124 120 121 136

Malaria
Prevention of Malaria
Oral

Children ≥8 years of age: 2 mg/kg (up to 100 mg) once daily.122 123 139 153

Initiate prophylaxis 1–2 days prior to entering malarious area; continue during the stay and for 4 weeks after leaving area.111 122 123 139 If there are concerns about tolerance or drug interactions, it may be advisable to initiate prophylaxis 3–4 weeks prior to travel in individuals receiving other drugs to ensure that the combination of drugs is well tolerated and to allow ample time if a switch to another antimalarial is required.123

Terminal prophylaxis with primaquine may be indicated during the final 2 weeks of doxycycline prophylaxis if exposure occurred in areas where P. ovale or P. vivax are endemic.122 123

Treatment of Uncomplicated Chloroquine-resistant P. falciparum Malaria
Oral

Children ≥8 years of age: 4 mg/kg daily given in 2 equally divided doses (up to 200 mg daily) for 7 days; used in conjunction with oral quinine sulfate (10 mg/kg 3 times daily given for 3 days if infection was acquired in Africa or South America or for 7 days if acquired in Southeast Asia).122 158

Treatment of Uncomplicated P. vivax Malaria
Oral

Children ≥8 years of age: 4 mg/kg daily in 2 equally divided doses (up to 200 mg daily) for 7 days; used in conjunction with oral quinine sulfate (10 mg/kg 3 times daily given for 3 days if infection was acquired in Africa or South America or for 7 days if acquired in Southeast Asia).158

In addition, a 14-day regimen of oral primaquine (0.6 mg/kg once daily) may be indicated to provide a radical cure and prevent delayed attacks or relapse of P. vivax malaria.158

Treatment of Severe P. falciparum Malaria
Oral

Children ≥8 years of age: 4 mg/kg daily in 2 equally divided doses (up to 200 mg daily) given for 7 days; used in conjunction with IV quinidine gluconate (followed by oral quinine sulfate) given for a total duration of 3–7 days.158 159

IV, then Oral

Children ≥8 years of age weighing <45 kg: Initially 4 mg/kg daily in 2 equally divided doses IV; when oral therapy can be tolerated, switch to oral doxycycline in a dosage of 4 mg/kg daily in 2 equally divided doses (up to 200 mg daily) for a total duration of IV and oral doxycycline of 7 days.158 Used in conjunction with IV quinidine gluconate (followed by oral quinine sulfate) given for a total duration of 3–7 days.158

Children ≥8 years of age weighing ≥45 kg: Initially 100 mg of doxycycline IV every 12 hours; when oral therapy can be tolerated, switch to oral doxycycline in a dosage of 100 mg every 12 hours for a total duration of IV and oral doxycycline of 7 days.158 Used in conjunction with IV quinidine gluconate (followed by oral quinine sulfate) given for a total duration of 3–7 days.158

Presumptive Self-treatment of Malaria
Oral

Children ≥8 years of age: 4 mg/kg daily in 2 equally divided doses for 7 days; used in conjunction with oral quinine sulfate (10 mg/kg 3 times daily given for 3 days if infection was acquired in Africa or South America or for 7 days if acquired in Southeast Asia).122 Initiate presumptive self-treatment if malaria is suspected (fever, chills, or other influenza-like illness) and professional medical care will not be available within 24 hours.122

Not recommended for self-treatment of malaria in individuals currently taking the drug for prophylaxis.122

Nongonococcal Urethritis
Oral

Adolescents: 100 mg twice daily given for 7 days.107

Pelvic Inflammatory Disease
Oral

Adolescents: 100 mg every 12 hours given for 14 days.107 Used in conjunction with and as follow-up to other anti-infectives (see Uses).107

IV, then Oral

Adolescents: 100 mg every 12 hours.107 Initially, IV doxycycline in conjunction with IV cefoxitin or cefotetan.107 Switch IV doxycycline to oral doxycycline in the same dosage as soon as possible and continue for a total duration of 14 days; continue IV cephamycin for ≥24 hours after clinical improvement occurs.107

Plague
Treatment of Pneumonic Plague Occurring in Context of Biologic Warfare or Bioterrorism
IV, then Oral

Children weighing <45 kg: 2.2 mg/kg twice daily (up to 200 mg daily).144

Children weighing ≥45 kg: 100 mg twice daily or 200 mg once daily.144

Prompt initiation of treatment (within 18–24 hours of symptom onset) is essential.144 147 Oral doxycycline may be substituted in the same dosage when the patient’s condition improves or if parenteral doxycycline is unavailable.144 147 Total duration of treatment is ≥10–14 days.144 147

Postexposure Prophylaxis Following High-risk Exposure
Oral

Children weighing <45 kg: 2.2 mg/kg twice daily (up to 200 mg daily).144

Children weighing ≥45 kg: 100 mg twice daily.144 Alternatively, 2–4 mg/kg daily in 2 equally divided doses.149

Duration of prophylaxis following exposure to plague aerosol or a patient with suspected pneumonic plague is 7 days144 147 or the duration of exposure risk plus 7 days.147

Rickettsial Infections
Oral

Children >8 years of age weighing ≤45 kg: 4.4 mg/kg in 2 divided doses on day 1 followed by 2.2 mg/kg daily in 1 or 2 divided doses.103 111 114 For severe infections, up to 4.4 mg/kg daily.103 111 114

Children >8 years of age weighing >45 kg: 100 mg every 12 hours on day 1 followed by 100 mg daily in 1 or 2 divided doses. For severe infections, 100 mg every 12 hours.103 111 114

Continue therapy for 3–10 days or until patient is afebrile for approximately 2–3 days.b Alternatively, a single 50-mg dose may be effective for louse-borne (epidemic) typhus, Brill-Zinsser disease, or scrub typhus.b

Rocky Mountain Spotted Fever (RMSF)
Oral or IV

CDC recommends 2.2 mg/kg (up to 100 mg) twice daily.cc Initiate promptly since delay can result in severe disease and fatal outcome.109 cc

Usually continued ≥5–10 days and until patient is afebrile for ≥3 days and clinically improved.109 x cc Severe illness may require longer duration of therapy.109 cc

IV therapy generally indicated for hospitalized patients; oral therapy generally appropriate for patients with early disease, those treated as outpatients, or inpatients who are not vomiting or obtunded.cc

Q Fever
Oral

CDC recommends 2.2 mg/kg every 12 hours for ≥14 days for treatment of acute Q fever.147

For prophylaxis against Q fever, 2.2 mg/kg twice daily given for 5–7 days may prevent clinical disease if initiated 8–12 days after exposure; such prophylaxis is not effective and may only prolong the onset of disease if given immediately (1–7 days) after exposure.147

Syphilis
Primary or Secondary Syphilis
Oral

Children >8 years of age: 100 mg twice daily given for 14 days.107 109 111 160

Latent Syphilis or Tertiary Syphilis (Except Neurosyphilis)
Oral

Children >8 years of age: 100 mg twice daily given for 14 days for early latent syphilis (duration <1 year) or 100 mg twice daily given for 28 days for late latent syphilis (duration≥1 year), latent syphilis of unknown duration, or tertiary syphilis.107 109 111 160

Tularemia
Treatment
IV, then Oral

Children weighing <45 kg: 2.2 mg/kg (up to 100 mg) twice daily.145 147

Children weighing ≥45 kg: 100 mg twice daily.145 147

Oral doxycycline may be substituted in the same dosage when the patient’s condition improves or if parenteral doxycycline is unavailable.145 Total duration of treatment is ≥14–21 days.145 147

Postexposure Prophylaxis Following High-risk Exposure
Oral

Children weighing <45 kg: 2.2 mg/kg (up to 100 mg) twice daily.145 147

Children weighing ≥45 kg: 100 mg twice daily.145 147

Initiate postexposure prophylaxis within 24 hours of exposure and continue for ≥14 days.145 147

Vibrio Infections
Cholera
Oral

Children ≥8 years of age: 6 mg/kg (maximum 300 mg) as a single dose.109

Prophylaxis in Sexual Assault Victims
Oral

Adolescents: 100 mg twice daily given for 7 days; used in conjunction with single doses of IM ceftriaxone and oral metronidazole.107

Adults

General Adult Dosage
Oral

100 mg every 12 hours on day 1 followed by 100 mg daily in 1 or 2 divided doses.103 111

For more severe infections, 100 mg every 12 hours.103 111

IV

200 mg on day 1 in 1 or 2 IV infusions followed by 100–200 mg daily.113

Respiratory Tract Infections
Legionella Infections
Oral

100 mg every 12 hours on the first day followed by 100 mg daily in 1 or 2 divided doses.a

For severe infections, 100 mg every 12 hours.a

Anthrax
Postexposure Prophylaxis Following Exposure in the Context of Biologic Warfare or Bioterrorism
Oral

100 mg twice daily given for ≥60 days.102 141 147 c Some experts recommend an initial 200-mg dose, then 100 mg every 12 hours.147

Optimum duration of postexposure prophylaxis after an inhalation exposure to B. anthracis spores is unclear,147 ff but prolonged postexposure prophylaxis usually required.102 147 A duration of 60 days may be adequate for a low-dose exposure, but a duration >4 months may be necessary to reduce the risk following a high-dose exposure.ff CDC and US Working Group on Civilian Biodefense recommend that postexposure prophylaxis following a confirmed exposure (including in laboratory workers with confirmed exposures to B. anthracis cultures) be continued for 60 days.102 147 The US Army Medical Research Institute of Infectious Diseases (USAMRIID) recommends that postexposure prophylaxis be continued for at least 60 days in individuals who are not fully immunized against anthrax and when anthrax vaccine is unavailable or cannot be used for postexposure vaccination.147

Treatment of Inhalational, GI, or Oropharyngeal Anthrax
Oral

100 mg twice daily.102 143 Some experts recommend an initial 200-mg dose, then 100 mg every 12 hours.147

Initial parenteral regimen preferred; use oral regimen for initial treatment only when a parenteral regimen is not available (e.g., when there are supply or logistic problems because large numbers of individuals require treatment in a mass casualty setting).102 143 Continue for total duration of ≥60 days if inhalational anthrax occurred as the result of exposure to anthrax spores in the context of biologic warfare or bioterrorism.102 143 147

IV, then Oral

100 mg twice daily.102 142 143 Some experts recommend an initial 200-mg dose, then 100 mg every 12 hours.147

Used in conjunction with 1 or 2 other anti-infectives predicted to be effective.102 143 When clinical improvement occurs, switch IV doxycycline to oral doxycycline in the same dosage and continue for a total duration of ≥60 days.102 142 143 147 d

Treatment of Cutaneous Anthrax
Oral

100 mg twice daily.102 143 147

For mild, uncomplicated cutaneous anthrax that occurs following natural or endemic exposure, 5–10 days of treatment has been recommended.102 143 147

For cutaneous anthrax that occurs following exposure in the context of biologic warfare or bioterrorism, duration of treatment is ≥60 days.102 143 147

Oral regimen should not be used for initial treatment of cutaneous anthrax if there are signs of systemic involvement, extensive edema, or head and neck lesions.102 143 147

IV, then Oral

100 mg twice daily.d 143

Used in conjunction with 1 or 2 other anti-infectives predicted to be effective.102 143 When clinical improvement occurs, switch IV doxycycline to oral doxycycline in the same dosage and continue for a total duration of ≥60 days.102 142 143 147 d

Bartonella Infections
Oral or IV

HIV-infected adults: 100 mg every 12 hours for ≥3 months for bartonellosis (including CNS infections).160 Also consider doxycycline long-term suppressive therapy in those with relapse or reinfection.160

Burkholderia Infections
Treatment of Localized Disease
Oral

Mild, localized disease without toxicity: 100 mg twice daily for 60–150 days may be effective.147

Localized disease without toxicity: 100 mg twice daily for 20 weeks given in conjunction with oral co-trimoxazole.147

Initial Treatment of Severe Disease
IV

100 mg twice daily given in conjunction with IV ceftazidime, imipenem, or meropenem.147 gg

Initial IV regimen continued for ≥14 days and until clinical improvement occurs.147 gg When appropriate, switch to a prolonged oral maintenance regimen.147 gg

Follow-up Maintenance Regimen after Initial Treatment of Severe Disease
Oral

100 mg twice daily given in conjunction with oral co-trimoxazole.147

Prolonged oral maintenance regimen recommended to reduce risk of relapse after initial treatment with IV ceftazidime, imipenem, or meropenem (with or without IV doxycycline).147 Maintenance regimen usually continued for ≥4–6 months;147 gg a duration of 6–12 months may be necessary depending on response to therapy and severity of illness.147 gg Lifelong follow-up recommended for all patients to identify relapse.147

Postexposure Prophylaxis
Oral

200 mg once daily in conjunction with oral rifampin.147 Optimum duration unknown; continue for ≥10 days.147

Brucellosis
Treatment of Brucellosis
Oral

Some experts recommend 100 mg twice daily.147

Usual duration is 4–6 weeks;109 147 more prolonged therapy may be required for complicated disease (e.g., hepatitis, splenitis, meningoencephalitis, endocarditis, osteomyelitis).147 Meningoencephalitis and endocarditis should be treated for ≥90 days and may require ≥6 months of treatment.147

Usually used in conjunction with rifampin or other anti-infectives to decrease risk of relapse.109 147 If infection is severe or if endocarditis, meningitis, or osteomyelitis is present, administer IM streptomycin or gentamicin during the first 1–3 weeks of doxycycline therapy.109 147

Postexposure Prophylaxis following Exposure in the Context of Biologic Warfare or Bioterrorism
Oral

200 mg once daily given for 3–6 weeks.147

Chlamydial Infections
Uncomplicated Urethral, Endocervical, or Rectal Infections
Oral

100 mg twice daily given for 7 days.103 107 108 111 114

Presumptive Treatment of Chlamydial Infection in Gonorrhea Patients
Oral

100 mg twice daily given for 7 days.107 108 109

Acute Epididymo-orchitis or Proctitis caused by C. trachomatis
Oral

100 mg twice daily given for ≥10 days.107 111

Lymphogranuloma Venereum
Oral

100 mg twice daily given for 21 days.107 108

Psittacosis (Ornithosis)
Oral

100 mg twice daily given for ≥10–14 days after defervescence.100

IV

4.4 mg/kg daily in 2 divided doses for initial treatment of severely ill patients.100

Ehrlichiosis
Oral or IV

CDC and others recommend 100 mg twice daily.109 x cc Initiate promptly since delay can result in severe disease and fatal outcome.109 cc

Optimum duration of therapy not established.109 x cc Usually continued ≥5–10 days and until patient is afebrile for ≥3 days and clinically improved.109 x cc Severe illness may require longer duration of therapy.109 cc CDC recommends a duration of 10–14 days in those with HGA since this provides an appropriate duration of therapy for possible concurrent early Lyme disease.cc

IV therapy generally indicated for hospitalized patients; oral therapy generally appropriate for patients with early disease, not requiring hospitalization, or inpatients who are not vomiting or obtunded.109 cc

Gonorrhea and Associated Infections
Uncomplicated Gonorrhea
Oral

100 mg twice daily given for 7 days recommended by manufacturer.111 Alternatively, 300 mg followed by another 300-mg dose 1 hour later.111

No longer recommended for gonorrhea by CDC or other experts.107 108

Empiric Treatment of Epididymitis
Oral

100 mg twice daily given for 10 days; as follow-up to a single dose of IM ceftriaxone.107 108 109

Epididymo-orchitis or Proctitis
Oral

100 mg twice daily given for ≥10 days for acute epididymo-orchitis or for 7 days for proctitis.107 111

Granuloma Inguinale (Donovanosis)
Oral

100 mg twice daily given for ≥3 weeks or until all lesions have healed completely;107 consider adding IV aminoglycoside (e.g., gentamicin) if improvement is not evident within the first few days of therapy and in HIV-infected patients.107

Relapse can occur 6–18 months after apparently effective treatment.116

Leptospirosis
Treatment
Oral

100 mg twice daily given for 7 days.b

Prevention
Oral

200 mg once weekly beginning 1–2 days prior to and continuing throughout the period of exposure.123 153

Lyme Disease
Early Localized or Early Disseminated Lyme Disease
Oral

100 mg twice daily.109 115 116 117 118 119 120 121 124 136 140

Duration of treatment is 14–21 days for most patients with early localized or early disseminated disease in the absence of neurologic involvement.109 115 116 117 118 119 120 121 124 136 140 Some experts recommend a duration of 21–28 days for early disseminated disease associated with mild carditis or isolated facial nerve palsy.109 115 136 140

Lyme Arthritis
Oral

100 mg twice daily given for 28 days.109 115 116 117 118 119 120 121 124 136

Acute Neurologic Manifestations (e.g., Meningitis, Radiculopathy)
Oral or IV

100–200 mg twice daily given for 14–28 days for patients who are intolerant of cephalosporins and penicillin.109 115 136 140

Malaria
Prevention of Malaria
Oral

100 mg once daily.111 122 123 139 153

Initiate prophylaxis 1–2 days prior to entering malarious area; continue during the stay and for 4 weeks after leaving area.111 122 153 If there are concerns about tolerance or drug interactions, it may be advisable to initiate prophylaxis 3–4 weeks prior to travel in individuals receiving other drugs to ensure that the combination of drugs is well tolerated and to allow ample time if a switch to another antimalarial is required.123

Terminal prophylaxis with primaquine may be indicated during the final 2 weeks of doxycycline prophylaxis if exposure occurred in areas where P. ovale or P. vivax are endemic.122 123

Treatment of Uncomplicated Chloroquine-resistant P. falciparum Malaria
Oral

100 mg twice daily for 7 days; used in conjunction with oral quinine sulfate (650 mg 3 times daily given for 3 days if infection was acquired in Africa or South America or for 7 days if acquired in Southeast Asia).122 158

Treatment of Uncomplicated P. vivax Malaria
Oral

100 mg twice daily for 7 days; used in conjunction with oral quinine sulfate (650 mg 3 times daily given for 3 days if malaria was acquired in Africa or South America or for 7 days if acquired in Southeast Asia).158

In addition, a 14-day regimen of oral primaquine (30 mg once daily) also may be indicated to provide a radical cure and prevent delayed attacks or relapse of P. vivax malaria.158

Treatment of Severe P. falciparum Malaria
Oral

100 mg twice daily given for 7 days; used in conjunction with IV quinidine gluconate (followed by oral quinine sulfate) given for a total duration of 3–7 days.158

IV, then Oral

Initially, 100 mg of doxycycline IV every 12 hours; when oral therapy can be tolerated, switch to oral doxycycline in a dosage of 100 mg every 12 hours for a total duration of IV and oral doxycycline of 7 days.158

Used in conjunction with IV quinidine gluconate (followed by oral quinine sulfate) given for a total duration of 3–7 days.158

Presumptive Self-treatment of Malaria
Oral

100 mg twice daily for 7 days; used in conjunction with oral quinine sulfate (650 mg 3 times daily given for 3 days if malaria was acquired in Africa or South America or for 7 days if acquired in Southeast Asia).122 Initiate presumptive self-treatment if malaria is suspected (fever, chills, or other influenza-like illness) and professional medical care will not be available within 24 hours.122

Not recommended for self-treatment of malaria in individuals currently taking the drug for prophylaxis.122

Mycobacterial Infections
Mycobacterium marinum Infections
Oral

100 mg twice daily given for ≥3 months recommended by ATS for treatment of cutaneous infections.106 A minimum of 4–6 weeks of treatment usually is necessary to determine whether the infection is responding.106

Nongonococcal Urethritis
Oral

100 mg twice daily given for 7 days.103 107 108 111 114

Pelvic Inflammatory Disease
Oral

100 mg every 12 hours given for 14 days.107 108 Used in conjunction with and as follow-up to other anti-infectives (see Uses).107 108

IV, then Oral

100 mg every 12 hours.107 108 Initially, IV doxycycline in conjunction with IV cefoxitin or cefotetan.107 108 Switch IV doxycycline to oral doxycycline in the same dosage as soon as possible and continue for a total duration of 14 days; continue IV cefoxitin or cefotetan for ≥24 hours after clinical improvement occurs.107 108

Plague
Treatment of Pneumonic Plague Occurring in Context of Biologic Warfare or Bioterrorism
IV, then Oral

100 mg every 12 hours or 200 mg once daily.144 147

Prompt initiation of treatment (within 18–24 hours of symptom onset) is essential.144 147 Oral doxycycline may be substituted in the same dosage when the patient’s condition improves or if parenteral doxycycline is unavailable.144 147 Total duration of treatment is ≥10–14 days.144 147

Postexposure Prophylaxis Following High-risk Exposure
Oral

100 mg every 12 hours.144 147 Alternatively, 100–200 mg daily in 2 equally divided doses.149

Duration of prophylaxis following exposure to plague aerosol or a patient with suspected pneumonic plague is 7 days144 147 or the duration of exposure risk plus 7 days.147

Pleural Effusions
Intrapleural

500 mg (diluted with 25–30 mL of 0.9% sodium chloride injection) instilled into the pleural space (see Intrapleural Administration Technique under Dosage and Administration).126 127 128 132 134 151 152 Procedure may be repeated to achieve control of the effusion,127 128 although repeated administration may have limited effects.126

For patients with recurrent malignant pleural effusions, administer a less concentrated 500-mg solution (diluted with 250 mL of 0.9% sodium chloride injection) via chest tube lavage and drainage.129 Clamp tube for 24 hours and repeat entire procedure daily until the drainage volume approximates the amount of solution instilled.129

Rickettsial Infections
Oral

100 mg every 12 hours on day 1 followed by 100 mg daily in 1 or 2 divided doses.103 111 114 For more severe infections, 100 mg every 12 hours.103 111 114

Continue therapy for 3–10 days or until patient is afebrile for approximately 2–3 days.b 109 Alternatively, a single dose of 100–200 mg may be effective for louse-borne (epidemic) typhus, Brill-Zinsser disease, or scrub typhus.b

Rocky Mountain Spotted Fever (RMSF)
Oral or IV

CDC and others recommend 100 mg twice daily.x cc Initiate promptly since delay can result in severe disease and fatal outcome.x cc

Usually continued ≥5–10 days and until patient is afebrile for ≥3 days and clinically improved.109 x cc Severe illness may require longer duration of therapy.109 cc

IV therapy generally indicated for hospitalized patients; oral therapy generally appropriate for patients with early disease, not requiring hospitalization, or inpatients who are not vomiting or obtunded.cc cc

Q Fever
Oral

100 mg twice daily given for 2–3 weeks recommended by CDC and others for acute Q fever.112 123 147 157

For acute Q fever with preexisting valvular heart disease, CDC recommends 200 mg daily given in conjunction with hydroxychloroquine for 1 year to prevent progression of acute disease to endocarditis.157 Patients with chronic Q fever endocarditis should receive the doxycycline and hydroxychloroquine regimen for 1.5–3 years.157

For prophylaxis against Q fever, 100 mg every 12 hours given for 5–7 days may prevent clinical disease if initiated 8–12 days after exposure; such prophylaxis is not effective and may only prolong the onset of disease if given immediately (1–7 days) after exposure.147

Syphilis
Primary or Secondary Syphilis
Oral

100 mg twice daily given for 14 days.107 108 111 160

IV

300 mg daily given for ≥10 days.113

Latent Syphilis or Tertiary Syphilis (Except Neurosyphilis)
Oral

100 mg twice daily given for 14 days for early latent syphilis (duration <1 year) or 100 mg twice daily given for 28 days for late latent syphilis (duration≥1 year), latent syphilis of unknown duration, or tertiary syphilis.107 108 109 111 160

Tularemia
Treatment
IV, then Oral

100 mg twice daily.145 147

Oral doxycycline may be substituted in the same dosage when the patient’s condition improves or if parenteral doxycycline is unavailable.145 Total duration of treatment is ≥14–21 days.145 147

Postexposure Prophylaxis Following High-risk Exposure
Oral

100 mg twice daily.145 147

Initiate postexposure prophylaxis within 24 hours of exposure and continue for ≥14 days.145 147

Vibrio Infections
Cholera
Oral

100 mg every 12 hours on the first day followed by 100 mg daily in 1 or 2 divided doses for 2 days.a For severe infections, 100 mg every 12 hours for 3 days.a

Alternatively, 300 mg as a single dose may be effective.110

Prophylaxis in Sexual Assault Victims
Oral

100 mg twice daily for 7 days; used in conjunction with single doses of IM ceftriaxone and oral metronidazole.107

Prescribing Limits

Pediatric Patients

General Pediatric Dosage
Oral

Maximum 4.4 mg/kg daily for severe infections in children >8 years of age weighing ≤45 kg.111

Malaria
Treatment of Uncomplicated Chloroquine-resistant P. falciparum Malaria
Oral

Children ≥8 years of age: Maximum 200 mg daily.158

Treatment of Uncomplicated P. vivax Malaria
Oral

Children ≥8 years of age: Maximum 200 mg daily.158

Treatment of Severe P. falciparum Malaria
Oral or IV

Children ≥8 years of age: Maximum 200 mg daily.158

Special Populations

Renal Impairment

Dosage adjustments not necessary.111

Cautions for Doxycycline Calcium

Contraindications

  • Known hypersensitivity to doxycycline or any tetracycline.103 111 113 114

Warnings/Precautions

Warnings

Dental and Bone Effects

Use during tooth development (e.g., pregnancy, children <8 years of age) may cause permanent yellow-gray to brown discoloration of teeth and enamel hypoplasia.111 113 Effects are most common following long-term use, but may occur following repeated short-term use.111 113

Tetracyclines form a stable calcium complex in any bone-forming tissue.111 113 Reversible decrease in fibula growth rate has occurred in prematures receiving oral tetracycline.111 113

Use not recommended in children <8 years of age unless other appropriate drugs are ineffective or are contraindicated or unless the benefits in certain indications (e.g., anthrax, ehrlichiosis, RMSF) outweigh the risks.109 111 113 cc (See Pediatric Use under Cautions.)

Superinfection/Clostridium difficile-associated Colitis

Possible emergence and overgrowth of nonsusceptible bacteria or fungi.111 113 Discontinue drug and institute appropriate therapy if superinfection occurs.111 113

Treatment with anti-infectives may permit overgrowth of clostridia.c Consider Clostridium difficile-associated diarrhea and colitis (antibiotic-associated pseudomembranous colitis) if diarrhea develops and manage accordingly.c

Some mild cases of C. difficile-associated diarrhea and colitis may respond to discontinuance alone.c r s t u v Manage moderate to severe cases with fluid, electrolyte, and protein supplementation; appropriate anti-infective therapy (e.g., oral metronidazole or vancomycin) recommended if colitis is severe.c r s t u v

Fetal/Neonatal Morbidity

Animal studies indicate possible fetal toxicity (e.g., retardation of skeletal development) and embryotoxicity.111 113 If used during pregnancy or if patient becomes pregnant while receiving doxycycline, patient should be apprised of the potential hazard to the fetus.111 (See Pregnancy under Cautions.)

Renal Effects

Tetracyclines have antianabolic effects and may increase BUN.111 113 Dose-related increase in BUN reported.111

Studies to date indicate that increased BUN does not occur with use of usual doxycycline doses in patients with impaired renal function.111 113

Sensitivity Reactions

Photosensitivity Reactions

Photosensitivity, manifested by an exaggerated sunburn reaction, reported with tetracyclines.111 113

Photosensitivity reactions may develop within a few minutes to several hours after sun exposure and usually persist 1–2 days after discontinuance of the drug.a Most reactions result from accumulation of tetracyclines in skin and are phototoxic in nature; photoallergic reactions also may occur.a

Discontinue drug at first evidence of skin erythema.111 113

Hypersensitivity Reactions

Oral suspension contains sulfites, which may cause allergic-type reactions (including anaphylaxis and life-threatening or less severe asthmatic episodes) in certain susceptible individuals.111

General Precautions

Nervous System Effects

Possibility of bulging fontanels in infants and benign intracranial hypertension in adults.111 Effects resolve when drug discontinued.111

Laboratory Monitoring

Periodically assess organ system function, including renal, hepatic and hematopoietic, during long-term therapy.111

Selection and Use of Anti-infectives

To reduce development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterials, use only for treatment or prevention of infections proven or strongly suspected to be caused by susceptible bacteria.c

When selecting or modifying anti-infective therapy, use results of culture and in vitro susceptibility testing.c In the absence of such data, consider local epidemiology and susceptibility patterns when selecting anti-infectives for empiric therapy.c

Because many strains of Acinetobacter, Bacteroides, Enterobacter, E. coli, Klebsiella, Shigella, S. pyogenes (group A β-hemolytic streptococci), S. pneumoniae, enterococci, and α-hemolytic streptococci are resistant to doxycycline, in vitro susceptibility tests should be performed if the drug is used for treatment of infections caused by these bacteria.111 113

Incision and drainage or other surgical procedures should be performed in conjunction with doxycycline therapy when indicated.111

Specific Populations

Pregnancy

Category D.111 (See Fetal/Neonatal Morbidity under Cautions.)

Should not be used in pregnant women unless, in the judgment of the clinician, it is essential for the welfare of the patient and benefits outweigh the risks.113

CDC and others state doxycycline can be used when necessary for treatment of inhalational anthrax in pregnant women.102 143 Since adverse effects on developing teeth and bones are dose-related, CDC suggests the drug might be used for a short period (7–14 days) before 6 months of gestation;143 some clinicians recommend periodic liver function testing if used in pregnant women.102

Malaria infection in pregnant women is associated with high risks of maternal and perinatal morbidity and mortality (e.g., miscarriage, premature delivery, low birth weight, congenital infection and/or perinatal death).158 CDC recommends prompt treatment with quinine and clindamycin for pregnant women with uncomplicated chloroquine-resistant P. falciparum malaria or with quinine alone for those with uncomplicated P. vivax malaria.158 However, CDC states a regimen of quinine in conjunction with doxycycline (or tetracycline) may be used for the treatment of uncomplicated malaria in pregnant women in rare circumstances (e.g., if other treatment options are not available or not tolerated) if benefits outweigh risks.158

CDC states tetracyclines (e.g., doxycycline) may be warranted in pregnant women with life-threatening illness when clinical suspicion of ehrlichiosis (including HGA and HGE) or RMSF is high.cc

Lactation

Distributed into milk;111 113 discontinue nursing or the drug.111

Short-term use in lactating women is not necessarily contraindicated, but the effects of prolonged exposure to doxycycline in breast milk (e.g., 60-day regimen for inhalational anthrax) are unknown.c AAP states maternal use of tetracyclines usually is compatible with breast-feeding since absorption of the drugs by nursing infants is negligible.109

Pediatric Use

Should not be used in children <8 years of age unless other appropriate drugs are ineffective or are contraindicated.109 111 113 (See Dental and Bone Effects under Cautions.)

Manufacturer, AAP, and CDC state use of tetracyclines (e.g., doxycycline) in children <8 years of age can be considered in certain unusual circumstances when benefits outweigh the risks (e.g., treatment of inhalational anthrax).109 111 cc

Recommended by AAP and CDC as drug of choice for presumed or confirmed Rickettsial infections (including RMSF) or ehrlichiosis (including HGA and HME) in children of any age.109 cc

CDC states that children <8 years of age with uncomplicated chloroquine-resistant P. falciparum malaria, uncomplicated P. vivax malaria, or severe P. falciparum malaria may receive a regimen that includes doxycycline (or tetracycline) if other treatment options are not available or not tolerated and the potential benefits outweigh risks.158

Hepatic Impairment

Pharmacokinetics not studied.

Renal Impairment

Renal impairment does not appear to result in excessive accumulation of the drug.103 111 113

Common Adverse Effects

GI effects (nausea, vomiting, diarrhea, bulky loose stools, anorexia, glossitis, dysphagia); maculopapular and erythematous rash; photosensitivity.111 113 a

Interactions for Doxycycline Calcium

Specific Drugs

Drug

Interaction

Comments

Antacids (aluminum-, calcium-, or magnesium-containing)

Decreased doxycycline absorption111

Avoid concomitant use103

Administer antacids containing aluminum, calcium, or magnesium 1–2 hours before or after doxycyclinea

Anticoagulants, oral

Possible increased anticoagulant effect;111 113 doxycycline may impair utilization of prothrombin or decrease vitamin K production by intestinal bacteria111 a

Monitor PT carefully; adjust anticoagulant dosage as needed111 113 a

Anticonvulsants (carbamazepine, barbiturates, phenytoin)

Possible decreased doxycycline half-life111 a

Demeclocycline, oxytetracycline, or tetracycline may be preferred when a tetracycline is indicated in a patient receiving carbamazepine, barbiturates, or phenytoina

Bismuth subsalicylate

Possible decreased absorption of doxycycline111 a

Concomitant use not recommendeda

Hormonal contraceptives

Possible decreased effectiveness of oral contraceptives111

Use alternative nonhormonal contraceptivesa

Iron-containing preparations

Possible decreased absorption of doxycycline103 111

Avoid concomitant use103

Administer doxycycline 2 hours before or 3 hours after an oral iron preparationa

Methoxyflurane

Possible fatal nephrotoxicity111

Concomitant use not recommendeda

Penicillins

Possible antagonism111 113 a

Concomitant use not recommended111 113 a

Doxycycline Calcium Pharmacokinetics

Absorption

Bioavailability

90–100% absorbed from GI tract in fasting adults;b peak serum concentrations attained within 1.5–4 hours.111 b

Food

GI absorption reduced up to 20% by food and/or milk;b effect not considered clinically important.111 b

Divalent and trivalent cations, including aluminum, calcium, iron, and magnesium, may decrease oral absorption as a result of chelation with the drug.b

Distribution

Extent

Widely distributed into body tissues and fluids.a

Only small amounts diffuse into CSF.a

Readily crosses the placentaa and is distributed into milk.111 a

Plasma Protein Binding

25–93%.a

Elimination

Metabolism

Does not appear to be metabolized in the liver, but is partially inactivated in the intestine by chelate formation.b

Elimination Route

Excreted into the GI tract via bile and by nonbiliary routes.111 b 20–26% of an oral or IV dose excreted in urine and 20–40% excreted in feces.111 113 b

Half-life

14–17 hours after a single dose and 22–24 hours after multiple doses.b

Special Populations

Patients with severe hepatic impairment or biliary obstruction: Serum concentrations and half-life may be increased.a

Patients with severe renal impairment: Half-life 18–26 hours after a single dose and 20–30 hours after multiple doses.b

Stability

Storage

Oral

Capsules

Doxycycline hyclate capsules: <30°C in a tight, light-resistant container.111

Doxycycline monohydrate capsules: 15–30°C and protect from light.114

Doxycycline hyclate delayed-release capsules containing partially enteric-coated pellets: <25°C.103

For Suspension

<30°C in a tight, light-resistant container.111 After reconstitution, stable for 2 weeks at room temperature.b

Suspension

<30°C in a tight, light-resistant container.111

Tablets

Film-coated tablets: <30°C in a tight, light-resistant container.111

Tablets: 15–30°C in a tight, light-resistant container.101

Film-coated tablets that have been ground and extemporaneously mixed with food or drinks (chocolate pudding, regular or low-fat chocolate milk, apple juice with table sugar, low-fat milk) are stable for 24 hours at room temperature (22–26°C) or refrigerated at 2–8°C; the ground tablets mixed with low-fat chocolate milk may be stable for 1 week when refrigerated.156 Ground tablets are stable for at least 6 days when wrapped in aluminum foil and stored at room temperature.156

Parenteral

Powder for Infusion

IV solutions containing 0.1–1 mg/mL prepared using sodium chloride or 5% dextrose injection are stable for 48 hours at 25°C when protected from direct sunlight or up to 72 hours when refrigerated and protected from both sunlight and artificial light.113 Once removed from refrigeration, these solutions must be completely infused within 12 hours and any unused solution discarded.113

IV solutions containing 0.1–1 mg/mL prepared using Ringer’s injection, invert sugar in 10% dextrose injection, Normosol-M or Normosol-R in 5% dextrose injection, or Plasma-Lyte 56 or Plasma-Lyte 148 in 5% dextrose injection are stable for up 12 hours at room temperature or up to 72 hours when refrigerated and protected from sunlight and artificial light.113 Once removed from refrigeration, these solutions must be completely infused within 12 hours and any unused solution discarded.113

IV solutions prepared using lactated Ringer’s injection or 5% dextrose in lactated Ringer’s injection must be completely infused within 6 hours after reconstitution and any unused solution discarded.113 These solutions must be protected from direct sunlight during infusion.113

Solutions containing 10 mg/mL prepared using sterile water for injection may be frozen immediately after preparation and stored for up to 8 weeks at -20°C.113 If warmed, take care to avoid heating after thawing is complete.113 Do not refreeze after thawing.113

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Solution Compatibility

Compatible

Dextrose 5% in Ringer’s injection, lactated113

Dextrose 5% in water113 HID

Invert sugar 10% in water113

Normosol M in dextrose 5%113 HID

Normosol R in dextrose 5%113 HID

Plasma-Lyte 56 or 148 in dextrose 5%113 HID

Ringer’s injection113 HID

Ringer’s injection, lactated113

Sodium chloride 0.9%113 HID

Drug Compatibility
Admixture CompatibilityHID

Compatible

Ranitidine HCl

Variable

Meropenem

Y-site CompatibilityHID

Compatible

Acyclovir sodium

Amifostine

Amiodarone HCl

Aztreonam

Bivalirudin

Cisatracurium besylate

Cyclophosphamide

Dexmedetomidine HCl

Diltiazem HCl

Docetaxel

Etoposide phosphate

Fenoldopam mesylate

Filgrastim

Fludarabine phosphate

Gemcitabine HCl

Granisetron HCl

Hetastarch in lactated electrolyte injection (Hextend)

Hydromorphone HCl

Linezolid

Magnesium sulfate

Melphalan HCl

Meperidine HCl

Morphine sulfate

Ondansetron HCl

Propofol

Remifentanil HCl

Sargramostim

Tacrolimus

Telavancin HCl

Teniposide

Theophylline

Thiotepa

Vinorelbine tartrate

Incompatible

Allopurinol sodium

Heparin sodium

Pemetrexed disodium

Piperacillin sodium and tazobactam sodium

Variable

Hetastarch in 0.9% sodium chloride

Meropenem

Actions and Spectrum

  • Usually bacteriostatic,111 113 a but may be bactericidal in high concentrations or against highly susceptible organisms.a

  • Inhibits protein synthesis111 113 in susceptible organisms by reversibly binding to 30S and 50S ribosomal subunits.a

  • The complete mechanisms by which tetracyclines reduce acne lesions have not been fully elucidated.a The effects appear to result in part from the antibacterial activity of the drugs, but other mechanisms also are involved.a

  • Spectrum of activity includes many gram-positive and -negative bacteria and various other organisms (e.g., Rickettsia, Chlamydia, Mycoplasma, spirochetes).111 a Inactive against fungi and viruses.111 a

  • Gram-positive aerobes and anaerobes: Active against Actinomyces israelii, Bacillus anthracis, Clostridium perfringens, C. tetani, Nocardia, Propionibacterium acnes, and some streptococci.111 a Many strains of S. pyogenes and Enterococci are resistant.111

  • Gram-negative aerobes and anaerobes: Active against Bartonella bacilliformis, Brucella, Calymmatobacterium granulomatis, Francisella tularensis, Haemophilus ducreyi, H. influenzae, Neisseria gonorrhoeae, Vibrio cholerae, Y. enterocolitica, and Y. pestis.111 a Many strains of Acinetobacter, E. aerogenes, E. coli, Klebsiella, and Shigella and nearly all strains of Proteus and Pseudomonas are resistant.111 a

  • Other organisms: Active against Rickettsia, Anaplasma phagocytophilum (formerly Ehrlichia phagocytophila, E. equi, agent of HGE),z dd ee E. chaffeensis,aa Coxiella burnetii, Chlamydia psittaci, C. trachomatis, Helicobacter pylori, Mycoplasma hominis, M. pneumoniae, Ureaplasma urealyticum, Borrelia burgdorferi, B. recurrentis, Leptospira, Treponema pallidum, T. pertenue, and Mycobacterium fortuitum.111 a Active against asexual erythrocytic forms of Plasmodium falciparum, but is not gametocidal and not active against exoerythrocytic forms of P. falciparum.111 a

  • Complete cross-resistance usually occurs between doxycycline and other tetracyclines (demeclocycline, minocycline, oxytetracycline, tetracycline).111 113 a

Advice to Patients

  • Advise patients that antibacterials (including doxycycline) should only be used to treat bacterial infections and not used to treat viral infections (e.g., the common cold).c

  • Importance of completing full course of therapy, even if feeling better after a few days.111 c

  • Advise patients that skipping doses or not completing the full course of therapy may decrease effectiveness and increase the likelihood that bacteria will develop resistance and will not be treatable with doxycycline or other antibacterials in the future.c

  • Importance of drinking sufficient quantities of fluids when taking capsules or tablets to reduce the risk of esophageal irritation and ulceration.111

  • Advise patients that doxycycline absorption is reduced when taken with foods, especially those containing calcium, but is not markedly influenced by simultaneous ingestion with food or milk.111

  • Advise patients that doxycycline may increase the incidence of vaginal candidiasis.111

  • Advise patients that doxycycline may decrease effectiveness of oral contraceptives and that alternative nonhormonal contraceptive measures should be used.a

  • Advise patients to avoid excessive sunlight or artificial UV light and to discontinue the drug at the first sign of skin erythema and if phototoxicity (e.g., skin eruption) occurs;111 consider use of sunscreen or sunblock.111

  • Advise patients using the drug for malaria prevention that no antimalarial agent (including doxycycline) guarantees protection against malaria.111 Importance of using personal protective measures to avoid mosquito bites (e.g., staying in well-screened areas, using mosquito nets, covering body with clothing, using an effective insect repellent), especially from dusk to dawn.111

  • Advise patients using the drug for malaria prevention that such prophylaxis should begin 1–2 days before travel to the malarious area, be taken daily while in the malarious area, and continued for 4 weeks (but not >4 weeks) after leaving the area.111

  • Advise travelers who plan presumptive self-treatment in the event of a possible malarial infection to keep an amount of doxycycline and quinine sufficient for self-treatment in their possession during travel and to take the regimen promptly in the event of a febrile illness during or after their travel if professional medical care is not readily available.122 158

  • Advise travelers that presumptive self-treatment of malaria is an interim measure and that they should seek medical evaluation as soon as possible.122 158

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.111 (See Fetal/Neonatal Morbidity under Cautions.)

  • Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs, and any concomitant illnesses.111

  • Importance of informing patients of other important precautionary information. (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Doxycycline Calcium

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Suspension

50 mg (of doxycycline) per 5 mL

Vibramycin Calcium Syrup

Pfizer

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Doxycycline Hyclate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules

50 mg (of doxycycline)*

Vibramycin Hyclate

Pfizer

100 mg (of doxycycline)*

Vibramycin Hyclate

Pfizer

Capsules, delayed-release (containing partially enteric-coated pellets)

100 mg (of doxycycline)

Doryx

Warner Chilcott

Tablets, film-coated

100 mg (of doxycycline)*

Vibra-Tabs

Pfizer

Parenteral

For injection, for IV use only

100 mg (of doxycycline)

Doxy 100

American Pharmaceutical Partners

Vibramycin Hyclate Intravenous

Pfizer

200 mg (of doxycycline)

Vibramycin Hyclate Intravenous

Pfizer

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Doxycycline Monohydrate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules

50 mg (of doxycycline)*

Doxycycline Monohydrate Capsules

Monodox

Oclassen

100 mg (of doxycycline)*

Doxycycline Monohydrate Capsules

Monodox

Oclassen

For suspension

25 mg (of doxycycline) per 5 mL

Vibramycin Monohydrate

Pfizer

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2014. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Adoxa 100MG Tablets (DOAK DERMATOLOGICS): 30/$407.97 or 90/$1,169.97

Adoxa 150MG Capsules (PHARMADERM): 60/$1,706.29 or 180/$4,962.34

Adoxa 75MG Tablets (DOAK DERMATOLOGICS): 30/$381.99 or 90/$1,105.96

Doryx 100MG Enteric-coated Tablets (WARNER CHILCOTT PROF PROD DIV): 30/$317.98 or 90/$902.99

Doryx 150MG Enteric-coated Tablets (WARNER CHILCOTT PROF PROD DIV): 60/$1,039.99 or 180/$3,019.90

Doryx 75MG Enteric-coated Tablets (WARNER CHILCOTT PROF PROD DIV): 30/$244.72 or 90/$689.95

Doxycycline Hyclate 100MG Capsules (WEST-WARD): 30/$12.99 or 60/$19.97

Doxycycline Hyclate 100MG Enteric-coated Tablets (MYLAN): 30/$287.98 or 90/$850.00

Doxycycline Hyclate 100MG Tablets (WEST-WARD): 20/$13.99 or 60/$41.97

Doxycycline Hyclate 20MG Tablets (LANNETT): 30/$39.99 or 90/$99.97

Doxycycline Hyclate 50MG Capsules (WEST-WARD): 20/$12.99 or 60/$29.97

Doxycycline Monohydrate 100MG Capsules (PAR): 30/$69.99 or 90/$199.97

Doxycycline Monohydrate 100MG Tablets (PAR): 50/$229.98 or 150/$618.64

Doxycycline Monohydrate 150MG Tablets (PAR): 30/$245.99 or 90/$689.95

Doxycycline Monohydrate 50MG Capsules (PAR): 30/$42.99 or 90/$117.98

Doxycycline Monohydrate 50MG Tablets (PAR): 100/$219.99 or 300/$539.92

Doxycycline Monohydrate 75MG Tablets (PAR): 30/$75.99 or 90/$205.97

Monodox 100MG Capsules (AQUA PHARMACEUTICALS): 50/$782.02 or 150/$2,293.08

Monodox 75MG Capsules (AQUA PHARMACEUTICALS): 100/$1,402.56 or 300/$4,207.68

Oracea 40MG Delayed-release Capsules (GALDERMA): 30/$430.01 or 90/$1,244.93

Vibra-Tabs 100MG Tablets (PFIZER U.S.): 20/$129.99 or 60/$379.98

Vibramycin 100MG Capsules (PFIZER U.S.): 20/$129.99 or 60/$379.98

Vibramycin 25MG/5ML Suspension (PFIZER U.S.): 60/$35.99 or 180/$84.97

Vibramycin 50MG/5ML Syrup (PFIZER U.S.): 480/$277.17 or 960/$538.95

AHFS DI Essentials. © Copyright, 2004-2014, Selected Revisions June 20, 2013. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

100. Centers for Disease Control and Prevention. Compendium of measures to control Chlamydia psittaci infection among humans (psittacosis) and pet birds (avian chlamydiosis), 2000. MMWR Morb Mortal Wkly Rep. 2000; 49(No. RR-8):1-17. [IDIS 439515] [PubMed 10993565]

101. CollaGenex Pharmaceuticals. Periostat (doxycycline hyclate) 20 mg tablets prescribing information. Newtown, PA; 2001 Apr.

102. Inglesby TV, O’Toole T, Henderson DA et al. Anthrax as a biological weapon, 2002. Updated recommendations for management. JAMA. 2002; 287:2236-52. [IDIS 480001] [PubMed 11980524]

103. Warner Chilcott. Doryx (doxycycline hyclate) coated pellets prescribing information (dated Dec 1999). In: Physicians’ desk reference. 56th ed. Montvale, NJ: Medical Economics Company Inc; 2002:3357-8.

104. Centers for Disease Control and Prevention. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2000; 49(No RR-15): 1-22.

105. Centers for Disease Control and Prevention. Update: interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children and mothers. MMWR Morb Mortal Wkly Rep. 2001; 50:1014-6. [PubMed 11724160]

106. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med. 1997; 156:S1-25.

107. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Morb Mortal Wkly Rep. 2002; 51(No. RR-6):1-78.

108. Anon. Treatment of sexually transmitted diseases. Med Lett Treat Guid. 2004; 2:67-74.

109. Committee on Infectious Diseases, American Academy of Pediatrics. Red book: 2003 report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003.

110. Guerrant RL, Gilder TV, Steiner TS et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis. 2001; 32:331-50. [IDIS 466024] [PubMed 11170940]

111. Pfizer. Vibramycin calcium (doxycycline calcium) syrup, Vibramycin hyclate (doxycycline hyclate) capsules, Vibramycin monohydrate (doxycycline monohydrate) for oral suspension, Vibra-tabs (doxycycline hyclate) film-coated tablets prescribing information. New York, NY. 2001 Nov.

112. Raoult D, Marrier T. Q fever. Clin Infect Dis. 1995; 20:489-96. [IDIS 345228] [PubMed 7756465]

113. Pfizer. Vibramycin hyclate (doxycycline hyclate) intravenous prescribing information (dated Mar 1991). In: Physicians’ desk reference. 56th ed. Montvale, NJ: Medical Economics Company Inc; 2002:2737-8.

114. Oclassen Pharmaceuticals, Inc. Monodox (doxycycline monohydrate) capsules prescribing information (dated Jan 12, 1999). In: Physicians’ desk reference. 56th ed. Montvale, NJ: Medical Economics Company Inc; 2002:2442-4.

115. Anon. Treatment of Lyme disease. Med Lett Drugs Ther. 2000; 42:37-9. [PubMed 10825919]

116. Nocton JJ, Steere AC. Lyme disease. Adv Intern Med. 1995; 40:69-117. [PubMed 7747659]

117. Jantausch BA. Lyme disease, Rocky Mountain spotted fever, ehrlichiosis: emerging and established challenges for the clinician. Ann Allergy. 1994; 73:4-11. [IDIS 333813] [PubMed 8030801]

118. Nadelman RB, Wormser GP. Erythema migrans and early Lyme disease. Am J Med. 1995; 98(4A):15-23S.

119. Sigal LH. Early disseminated Lyme disease: cardiac manifestations. Am J Med. 1995; 98(4A):25-28S.

120. Steere AC. Musculoskeletal manifestations of Lyme disease. Am J Med. 1995; 98(4A):44-48S.

121. Sigal LH. Managment of Lyme disease refractory to antibiotic therapy. Rheum Dis Clin North Am. 1995; 21:217- 30. [PubMed 7732170]

122. Anon. Drugs for parasitic infections. Med Lett Drugs Ther. Aug 2004. From the Medical Letter website. Accessed 2005 Feb 2.

123. Centers for Disease Control and Prevention. Health information for international travel, 2003–2004. Atlanta, GA: US Department of Health and Human Services; 2003:13-39,96-7,99-116,125-7,134-9,187-8,227,231-5,240-2,249-50. Updates available from CDC website.

124. Rahn DW, Malawista SE. Lyme disease: recommendations for diagnosis and treatment. Ann Intern Med. 1991; 114:472-81. [IDIS 278982] [PubMed 1994795]

125. Anon. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med. 2001; 345:79-84. [IDIS 467348] [PubMed 11450675]

126. Reviewers’ comments (personal observations).

127. Kitamura S, Sugiyama Y, Izumi T et al. Intrapleural doxycycline for control of malignant pleural effusion. Curr Ther Res. 1981; 30:515-21.

128. Mansson T. Treatment of malignant pleural effusion with doxycycline. Scand J Infect Dis Suppl. 1988; 53:29-34. [PubMed 3166542]

129. Muir JF, Defouilloy C, Ndarurinze S et al. [Use of intrapleural doxycycline via lavage-drainage in recurrent effusions of neoplastic origin]. Rev Mal Respir. 1987; 4:29-33. [PubMed 3589104]

130. Hausheer FH, Yarbro JW. Diagnosis and treatment of malignant pleural effusion. Semin Oncol. 1985; 12:54-75. [PubMed 2579439]

131. Ruckdeschel JC, Moores DW. Recent findings in the clinical management of malignant pleural effusions: continuing medical education monograph. Albany, NY: The Albany Medical College: 1990 May (publication No. N-W2680).

132. Gericke KR. Doxycycline as a sclerosing agent. Ann Pharmacother. 1992; 26:648-9. [IDIS 296423] [PubMed 1375521]

133. Ruckdeschel JC. Management of malignant pleural effusion: an overview. Semin Oncol. 1988; 15(Suppl 3):24-8. [PubMed 3293215]

134. Vaughan LM, Walker PB, Sahn SA. Alternatives to tetracycline pleurodesis. Ann Pharmacother. 1992; 26:562-3. [IDIS 294133] [PubMed 1576396]

135. Landvater L, Hix WR, Mills M et al. Malignant pleural effusion treated by tetracycline sclerotherapy: a comparison of single vs repeated instillation. Chest. 1988; 93:1196-8. [IDIS 242531] [PubMed 3371098]

136. Wormser GP, Nadelman RB, Dattwyler R et al. Infectious Diseases Society of America. Practice guidelines for the treatment of Lyme disease. Clin Infect Dis. 2000; 31:(Suppl 1):S1-14. [PubMed 10982743]

137. Anon. The choice of antibacterial drugs. Med Lett Treat Guid. 2004; 2:13-26.

138. Shapiro ED. Doxycycline for tick bites—not for everyone. N Engl J Med. 2001; 345:133-4. [IDIS 467352] [PubMed 11450662]

139. World Health Organization. International travel and health: vaccination requirements and health advice. World Health Organization; 2001. From WHO web site.

140. Steere AC. Lyme disease. N Engl J Med. 2001; 345:115-25. [IDIS 467351] [PubMed 11450660]

141. Centers for Disease Control and Prevention. Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR. 2001: 50:889-893.

142. Food and Drug Administration. Notice regarding doxycycline and penicillin G procaine administration for inhalational anthrax (post-exposure). 2001 Oct 30. From FDA website.

143. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep. 2001; 50:909-19. [IDIS 471910] [PubMed 11699843]

144. Inglesby TV, Dennis DT, Henderson DA et al for the Working Group on Civilian Biodefense. Plague as a biological weapon: medical and public health management. JAMA. 2000; 283:2281-90. [IDIS 446671] [PubMed 10807389]

145. Dennis DT, Inglesby TV, Henderson DA et al for the Working Group on Civilian Biodefense. Tularemia as a biological weapon: medical and public health management. JAMA. 2001; 285:2763-73. [IDIS 465175] [PubMed 11386933]

146. Barza M, Schiefe RT. Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics part 1: tetracyclines. Am J Hosp Pharm. 1977; 34:49-57. [IDIS 67424] [PubMed 318799]

147. US Army Medical Research Institute of Infectious Disease. USAMRIID’s medical management of biologic casualties handbook. 5th ed. USAMRIID: Fort Detrick, MD; 2004 Aug.

148. Reynolds JEF, ed. Martindale: the extra pharmacopoeia. 30th ed. London: The Pharmaceutical Press; 1993:212-6.

149. Centers for Disease Control and Prevention. Prevention of plague: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1996; 45:1-15. [PubMed 8531914]

150. Neuvonen PJ. Interactions with the absorption of tetracyclines. Drugs. 1976; 11:45-54. [IDIS 62491] [PubMed 946598]

151. Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Arch Intern Med. 1994; 120:56-64.

152. Heffner JE, Standerfer J, Torstveit J et al. Clinical efficacy of doxycycline for pleurodesis. Chest. 1994; 105:1743-7. [IDIS 332086] [PubMed 8205870]

153. Anon. Advice for travelers. Med Lett Treat Guide. 2004; 2:33-40.

154. DuPont HL, Ericsson CD. Prevention and treatment of traveler’s diarrhea. N Engl J Med. 1993; 328:1821-7. [IDIS 315863] [PubMed 8502272]

155. Xu LX, Nguyenpho A, Roberts R et al. Palatability evaluations of doxycycline solid dosage tablets ground and mixed in foods or drinks. From the FDA website.

156. Brower JF, Moore TW, Reepmeyer JC et al. Stability and dose uniformity evaluations of doxycycline solid dosage tablets ground and mixed in foods or drinks. From the FDA website.

157. Centers for Disease Control and Prevention. Q fever—California, Georgia, Pennsylvania, and Tennessee, 2000-2001. MMWR Morb Mortal Wkly Rep. 2002; 51:924-5. [PubMed 12403408]

158. Centers for Disease Control and Prevention. CDC treatment guidelines: Treatment of malaria (guidelines for clinicians). 2004 Jun 28. From the CDC website. Accessed 2004 Oct 25.

159. Paris M (Malaria Division, US Centers for Disease Control. Atlanta, GA): Personal communication; 2004 Nov 12.

160. Centers for Disease Control and Prevention. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep. 2004; 53(No. RR-15):1-112.

a. AHFS Drug Information 2004. McEvoy GK, ed. Tetracyclines General Statement. American Society of Health-System Pharmacists; 2004:433-49.

b. AHFS Drug Information 2004. McEvoy GK, ed. Doxycycline Calcium, Doxycycline Hyclate, Doxycycline Monohydrate. American Society of Health-System Pharmacists; 2004:449-53.

c. Pfizer. Vibramycin calcium (doxycycline calcium) oral suspension syrup, Vibramycin hyclate (doxycycline hyclate) capsules, Vibramycin monohydrate (doxycycline monohydrate) for oral suspension, Vibra-tabs (doxycycline hyclate) film coated tablets prescribing information. New York, NY. 2003 Sep.

d. Pfizer. Vibramycin hyclate (doxycycline hyclate) intravenous prescribing information. New York, NY. 2001 Nov.

e. Spach DH, Kanter AS, Dougherty MJ et al. Bartonella (Rochalimaea) quintana bacteremia in inner-city patients with chronic alcoholism. N Engl J Med. 1995; 332:424-8. [PubMed 7529895]

f. Bass JW, Vincent JM, Person DA. The expanding spectrum of Bartonella infections: I. Bartonellosis and trench fever. Pediatr Infect Dis J. 1997; 16:2-10. [IDIS 379701] [PubMed 9002093]

g. Spach DH, Koehler JE. Bartonella-associated infections. Infect Dis Clin N Am. 1998; 12:137-55.

h. US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA) Prevention of Opportunistic Infections Working Group. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons with human immunodeficiency virus. From the US Department of Health and Human Services HIV/AIDS Information Services (AIDSinfo) website.

i. Mui BSK, Mulligan ME, George WL. Response of HIV-associated disseminated cat scratch disease to treatment with doxycycline. Am J Med. 1990; 89:229-31. [IDIS 270068] [PubMed 2382670]

j. Tan JS. Human zoonotic infections transmitted by dogs and cats. Arch Intern Med. 1997; 157:1933-43. [IDIS 394193] [PubMed 9308505]

k. Bass JW, Freitas BC, Freitas AD et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J. 1998; 17:447-52. [IDIS 408829] [PubMed 9655532]

l. Smith DL. Cat-scratch disease and related clinical syndromes. Am Fam Physician. 1997; 55:1783-9. [IDIS 384830] [PubMed 9105205]

m. Ariza J, Gudiol F, Pallares R et al. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin: a randomized, double-blind study. Ann Intern Med. 1992; 117:25-30. [IDIS 298554] [PubMed 1596044]

n. Solera J, Rodriquez-Zapata M, Geijo P et al. Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. Antimicrob Agents Chemother. 1995; 39:2061-7. [IDIS 353842] [PubMed 8540716]

o. Dixon TC, Meselson M, Guillemin J et al. Anthrax. N Engl J Med. 1999; 341:815-26. [IDIS 432452] [PubMed 10477781]

p. Centers for Disease Control and Prevention. Diagnosis and management of foodborne illness. A primer for physicians. MMWR Morb Mortal Wkly Rep. 2001; 50(RR-2):1-69. [PubMed 11215787]

q. Centers for Disease Control and Prevention. Vibrio vulnificus infections associated with eating raw oysters—Los Angeles, 1996. MMWR Morb Mortal Wkly Rep. 1996; 45:621-4. [PubMed 8965788]

r. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis. 1998; 26:1027-36. [IDIS 407733] [PubMed 9597221]

s. Gerding DN, Johnson S, Peterson LR et al for the Society for Healthcare Epidemiology of America. Position paper on Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995; 16:459-77. [PubMed 7594392]

t. Fekety R for the American College of Gastroenterology Practice Parameters Committee. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol. 1997; 92:739-50. [IDIS 386628] [PubMed 9149180]

u. American Society of Health-System Pharmacists Commission on Therapeutics. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health-Syst Pharm. 1998; 55:1407-11. [IDIS 407213] [PubMed 9659970]

v. Wilcox MH. Treatment of Clostridium difficile infection. J Antimicrob Chemother. 1998; 41(Suppl C):41-6. [IDIS 407246] [PubMed 9630373]

HID. Trissel LA. Handbook on injectable drugs. 17th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013:424-7.

x. Walker DH, Dumler JS. Erlichia chaffeensis (human monocytropic erlichiosis), Anaplasma phagocytophillum (human granulocytropic anaplasmosis), and other Ehrlichieae. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 6th ed. New York: Churchill Livingstone; 2005:2310-18.

y. Dumler JS, Choi KS, Garcia-Garcia JC et al. Human granulocytic anaplasmosis and Anaplasma phagocytophilum. Emerg Infect Dis. 2005;11:1828-34.

z. Maurin M, Bakken JS, Dumler JS. Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States. Antimicrob Agents Chemother. 2003;47:413-5.

aa. Brouqui P, Raoult D. In vitro antibiotic susceptibility of the newly recognized agent of ehrlichiosis in humans, Ehrlichia chaffeensis. Antimicrob Agents Chemother. 1992;36:2799-803.

cc. Centers for Disease Control and Prevention. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis -United States: a practical guide for physicians and other health-care and public health professionals.. MMWR Morb Mortal Wkly Rep. 2006; 55(No RR-4): 1-27.

dd. Klein MB, Nelson CM, Goodman JL. Antibiotic susceptibility of the newly cultivated agent of human granulocytic ehrlichiosis: promising activity of quinolones and rifamycins. Antimicrob Agents Chemother. 1997;41:76-9.

ee. Horowitz HW, Hsieh TC, Aguero-Rosenfeld ME et al. Antimicrobial Susceptibility of Ehrlichia phagocytophila. Antimicrob Agents Chemother. 2001;45: 786-88.

ff. Brookmeyer R, Johnson E, Bollinger R. Modeling the optimum duration of antibiotic prophyalxis in an anthrax outbreak. Proc Natl Acad Sci. 2003; 100:10129-32. [PubMed 12890865]

gg. Bossi P, Tegnell A, Baka A et al. BICHAT guidelines for the clinical management of glanders and melioidosis and bioterrorism-related glanders and melioidosis. Euro Surveill. 2004; 9:1-6.

Suffering from knee pain? Find out how real people manage OA of the Knee. Watch Video

Close
Hide
(web4)